- Home
- AMZN vs AZN Comparison
AMZN vs AZN Comparison
Compare AMZN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZN | AZN |
|---|---|---|
| Founded | 1994 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6T | 316.4B |
| IPO Year | 1997 | 1995 |
Fundamental Metrics
Financial Performance| Metric | AMZN | AZN |
|---|---|---|
| Price | $260.82 | $169.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 42 | 1 |
| Target Price | ★ $285.88 | N/A |
| AVG Volume (30 Days) | ★ 41.0M | 4.1M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 29.66 | N/A |
| EPS | ★ 8.53 | N/A |
| Revenue | ★ $716,924,000,000.00 | N/A |
| Revenue This Year | $14.63 | $10.34 |
| Revenue Next Year | $11.81 | $6.43 |
| P/E Ratio | ★ $30.71 | $31.91 |
| Revenue Growth | ★ 12.38 | N/A |
| 52 Week Low | $196.00 | $72.90 |
| 52 Week High | $287.20 | $212.71 |
Technical Indicators
Market Signals| Indicator | AMZN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 53.08 |
| Support Level | $255.19 | $164.06 |
| Resistance Level | $276.66 | $175.04 |
| Average True Range (ATR) | 5.22 | 2.51 |
| MACD | -1.37 | 1.54 |
| Stochastic Oscillator | 23.74 | 96.89 |
Price Performance
Historical ComparisonAbout AMZN Amazon.com Inc.
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 74% of total, followed by Amazon Web Services (17%), and advertising services (9%). International segments constitute 22% of Amazon's total revenue, led by Germany, the United Kingdom, and Japan.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.